

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	168,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Group Art Unit	1649
Examiner Name	Marianne DiBrino

Attorney Docket Number

001107.00355

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
MD		5,583,031	December 10, 1996	Stern	
MD		6,015,884	January 18, 2000	Schneck <i>et al.</i>	
MD		6,140,113	October 31, 2000	Schneck <i>et al.</i>	
MD		6,448,071	September 10, 2002	Schneck <i>et al.</i>	
MD		6,458,354	October 1, 2002	Schneck <i>et al.</i>	
MD		6,268,411	July 31, 2001	Schneck <i>et al.</i>	
MD		US 2002/0119121	August 29, 2002	Vitiello <i>et al.</i>	
MD		US 2002/0122818	September 5, 2002	Albani	
MD		US 2003/0077248	April 24, 2003	Moriarty <i>et al.</i>	
MD		Serial No. 09/642,660	unpublished	Schneck <i>et al.</i>	
MD		2002/0006903	January 17, 2002	Schneck <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
MD		WO 01/94944	December 13, 2001	Memorial Sloan-Kettering Cancer Center		


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MD		Goldberg <i>et al.</i> , "In vivo Augmentation of Tumor-Specific CTL Responses by Class I/Peptide Antigen Complexes on Microspheres (Large Multivalent Immunogen)," <i>J. Immunol.</i> 170, 228-35, 2003	
MD		Latouche & Sadelain, "Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells," <i>Nature Biotechnol.</i> 18, 405-09, April 2000	
MD		Levine <i>et al.</i> , "Effects of CD28 Costimulation on Long-Term Proliferation of CD4+ T cells in the Absence of Exogenous Feeder Cells," <i>J. Immunol.</i> 159, 5921-30, 1997	
MD		Maus <i>et al.</i> , "Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB," <i>Nature Biotechnol.</i> 20, 143-48, February 2002	
MD		Maus <i>et al.</i> , "HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells," <i>Clin. Immunol.</i> 106, 16-22, 2003	

Examiner Signature	/Marianne DiBrino/	Date Considered	10/10/2006
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003, OMB 0651-0031

Approved for use through 04/30/2003. GMB 0531-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/618,267
		Filing Date	July 14, 2003
		First Named Inventor	Jonathan Schneck
		Art Unit	1644
		Examiner Name	Marianne DiBrino
		Attorney Docket Number	001107.00355
Sheet	1	of	1

U.S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Examiner Signature	/Marianne DiBrino/	Date Considered	10/10/2006
--------------------	--------------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

Approved for use through 04/06/2006. GPO 2001-0807

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1419A/BTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/618,267
		Filing Date	July 14, 2003
		First Named Inventor	Jonathan Schneck
		Art Unit	4644 1644
		Examiner Name	4644 /Marianne DiBrino/
Sheet	1	of	1
		Attorney Docket Number	001107.00355

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	/Marianne DiBrino/	Date Considered	10/10/2006
-----------------------	--------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See WIPO Standard Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.4. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete If Known

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneek
Group Art Unit	1614-1644
Examiner Name	Marianne DiBrino

MPEP 4493
DEC 14 2005
1614-1644
MARIANNE DiBRINO
U.S. PATENT & TRADEMARK OFFICE

Attorney Docket Number

001107.00355

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
MD		6,269,411	07/31/2001	REASONER	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
MD		WO 01/80833 A1	11/01/2001	Salvatore Albani		
MD		WO 02/065992 A2	08/29/2002	Ortho-McNeil Pharmaceutical, Inc.		
MD		WO 03/057171 A2	07/17/2003	The Trustees of the University of Pennsylvania		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MD		DEETHS et al., "B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4 ⁺ and CD8 ⁺ T cells", <i>European Journal of Immunology</i> , Vol. 27, No. 3, 1997, pp 598-608.	
MD		OELKE et al., "Generation and purification of CD8 ⁺ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy", <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , May 2000, Vol. 6, No. 5, pp 1997-2005.	
MD		VON BERGWELT-BAILDON et al., "Human primary and memory cytotoxic T lymphocyte responses are effectively induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application", <i>Blood</i> , Vol. 99, No. 9, May 1, 2002, pp 3319-3325.	
MD		OERTLI et al., "Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4 ⁺ lymphocytes invitro", <i>Clinical and Experimental Immunology</i> , Vol. 110, No. 1, October 1997, pp 144-149.	
MD		NAKAMURA et al., "Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor Immunity", <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , Vol. 8, No. 8, August 2002, pp 2742-2749.	
MD		OELKE et al., "Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells", <i>Nature Medicine</i> , Vol. 9, No. 5, May 2003, pp 619-624.	

Examiner Signature	/Marianne DiBrino/	Date Considered	10/10/2006
--------------------	--------------------	-----------------	------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.